Cidara Therapeutics (CDTX) News Today $64.85 +0.14 (+0.22%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$66.24 +1.40 (+2.15%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 MeetingSeptember 17 at 6:50 PM | markets.businessinsider.comCidara Therapeutics presents data on CD388 from Phase 2b NAVIGATE trialSeptember 17 at 6:50 PM | msn.comCidara Therapeutics Presents CD388 Efficacy and Safety Data from NAVIGATE Phase 2b Trial at ISRV ConferenceSeptember 17 at 8:30 AM | quiverquant.comQCidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingSeptember 17 at 8:00 AM | globenewswire.comInsider Selling: Cidara Therapeutics (NASDAQ:CDTX) Insider Sells 474 Shares of StockSeptember 16 at 8:42 PM | marketbeat.comNicole Negar Davarpanah Sells 474 Shares of Cidara Therapeutics (NASDAQ:CDTX) StockSeptember 16 at 5:10 AM | insidertrades.comCidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comAmerican Century Companies Inc. Purchases Shares of 10,409 Cidara Therapeutics, Inc. $CDTXSeptember 9, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys 620,046 Shares of Cidara Therapeutics, Inc. $CDTXSeptember 7, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $64.14 Consensus Target Price from AnalystsSeptember 7, 2025 | americanbankingnews.comCheckpoint Capital L.P. Trims Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 6, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Has $416,000 Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 6, 2025 | marketbeat.comBVF Inc. IL Has $19.92 Million Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 5, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Rating of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comCidara Therapeutics to Present at Upcoming Investor Conferences in September 2025September 4, 2025 | quiverquant.comQCidara Therapeutics to Participate in September Investor ConferencesSeptember 4, 2025 | globenewswire.comADAR1 Capital Management LLC Has $451,000 Stock Position in Cidara Therapeutics, Inc. $CDTXSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Acquires Shares of 504,542 Cidara Therapeutics, Inc. $CDTXSeptember 4, 2025 | marketbeat.comCidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingSeptember 3, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above 50-Day Moving Average - Time to Sell?September 1, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 120,879 Cidara Therapeutics, Inc. $CDTXAugust 24, 2025 | marketbeat.comCidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b ReadoutAugust 15, 2025 | seekingalpha.comCidara Therapeutics: Promising Trials Amidst Financial ChallengesAugust 13, 2025 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Buy" from AnalystsAugust 11, 2025 | marketbeat.comCidara Therapeutics Reports Positive Trial Results and Financial GrowthAugust 9, 2025 | theglobeandmail.comCidara Therapeutics (CDTX) Receives a Buy from NeedhamAugust 9, 2025 | theglobeandmail.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Down - Here's WhyAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst SaysAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 at HC WainwrightAugust 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 at Needham & Company LLCAugust 9, 2025 | marketbeat.comVivo Capital LLC Grows Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX)August 9, 2025 | marketbeat.comCidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCidara (CDTX) Q2 Cash Surges 163%August 8, 2025 | theglobeandmail.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | finance.yahoo.comWest Michigan Advisors LLC Takes $291,000 Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX)August 6, 2025 | marketbeat.comCidara Therapeutics (CDTX) Projected to Post Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Reaches New 12-Month High - Here's WhyJuly 25, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50 Day Moving Average - What's Next?July 25, 2025 | marketbeat.comCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025July 24, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Sets New 52-Week High - What's Next?July 19, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50-Day Moving Average - Here's WhyJuly 16, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from BrokeragesJuly 16, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Down 7.6% - What's Next?July 15, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Trading 5.9% Higher - Still a Buy?July 14, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Sees Strong Trading Volume - Here's WhyJuly 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Down - Here's What HappenedJuly 8, 2025 | marketbeat.comSegal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara TherapeuticsJuly 7, 2025 | businesswire.comWarner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist InvestorsJuly 3, 2025 | msn.comCidara Therapeutics (NASDAQ:CDTX) Sees Strong Trading Volume - What's Next?July 2, 2025 | marketbeat.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.670.63▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼74▲CDTX Articles Average Week Get the Latest News and Ratings for CDTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cidara Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cytokinetics News Today Axsome Therapeutics News Today Nuvalent News Today TG Therapeutics News Today Merus News Today CRISPR Therapeutics News Today PTC Therapeutics News Today Krystal Biotech News Today Vaxcyte News Today ACADIA Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
